Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Dose-Ranging Pharmacokinetic Study Comparing Investigational Oral Formulation with the Current Intravenous Formulation of Edaravone

Next Previous
Trial Profile

A Phase 1, Dose-Ranging Pharmacokinetic Study Comparing Investigational Oral Formulation with the Current Intravenous Formulation of Edaravone

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edaravone (Primary) ; Edaravone
  • Indications Amyotrophic lateral sclerosis
  • Focus Pharmacokinetics

Most Recent Events

  • 02 Dec 2018 New trial record
  • 15 Nov 2018 Results presented in a Media Release
  • 15 Nov 2018 According to a Mitsubishi Tanabe Pharma America media release, data collection from this study is ongoing and the latest results and its anticipated development plan will be presented at the upcoming Symposium.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top